Eurofins Scientific (ERF) | Financial Analysis & Statements
Eurofins Scientific SE Large-cap Healthcare
TL;DR: Financial Overview - Revenue, Profits & Key Metrics
Latest Quarterly: Jun 2018Income Metrics
EPS (Diluted)
€0.00
Balance Sheet Metrics
Total Assets
11.0B
Total Liabilities
6.4B
Shareholders Equity
4.6B
Debt to Equity
1.40
Cash Flow Metrics
Operating Cash Flow
33.2M
Free Cash Flow
31.6M
Revenue & Profitability Trend
Annual Income Flow
2025
Eurofins Scientific Income Statement From 2021 to 2025
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 7.3B | 7.0B | 6.5B | 6.7B | 6.7B |
| Cost of Goods Sold | 2.3B | 2.2B | 2.2B | 2.2B | 2.1B |
| Gross Profit | 5.0B | 4.7B | 4.4B | 4.5B | 4.6B |
| Gross Margin % | 68.1% | 67.8% | 67.0% | 66.8% | 68.0% |
| Operating Expenses | |||||
| Research & Development | - | - | - | - | - |
| Selling, General & Administrative | - | - | - | - | - |
| Other Operating Expenses | 58.6M | 46.0M | 50.3M | 16.4M | 38.2M |
| Total Operating Expenses | 58.6M | 46.0M | 50.3M | 16.4M | 38.2M |
| Operating Income | 818.3M | 726.2M | 546.8M | 783.2M | 1.3B |
| Operating Margin % | 11.2% | 10.4% | 8.4% | 11.7% | 19.0% |
| Non-Operating Items | |||||
| Interest Income | 10.6M | 19.3M | 11.6M | 2.2M | 2.0M |
| Interest Expense | 157.1M | 150.8M | 129.4M | 105.6M | 95.0M |
| Other Non-Operating Income | - | - | - | - | - |
| Pre-tax Income | 654.1M | 554.6M | 423.3M | 780.0M | 1.1B |
| Income Tax | 181.1M | 149.1M | 115.5M | 174.2M | 273.6M |
| Effective Tax Rate % | 27.7% | 26.9% | 27.3% | 22.3% | 25.9% |
| Net Income | 473.0M | 405.5M | 307.8M | 605.8M | 783.0M |
| Net Margin % | 6.5% | 5.8% | 4.7% | 9.0% | 11.7% |
| Key Metrics | |||||
| EBITDA | 1.6B | 1.4B | 1.2B | 1.4B | 1.7B |
| EPS (Basic) | €2.64 | €2.13 | €1.61 | €3.17 | €4.09 |
| EPS (Diluted) | €2.55 | €2.09 | €1.57 | €3.07 | €3.90 |
| Basic Shares Outstanding | 179800000 | 190600000 | 192900000 | 192500000 | 191500000 |
| Diluted Shares Outstanding | 179800000 | 190600000 | 192900000 | 192500000 | 191500000 |
Income Statement Trend
Eurofins Scientific Balance Sheet From 2021 to 2025
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Assets | |||||
| Current Assets | |||||
| Cash & Equivalents | 791.2M | 613.9M | 1.2B | 486.6M | 515.3M |
| Short-term Investments | - | - | - | - | - |
| Accounts Receivable | 1.1B | 1.1B | 1.1B | 1.1B | 1.1B |
| Inventory | 139.3M | 141.9M | 139.0M | 145.6M | 154.2M |
| Other Current Assets | 100.0K | -200.0K | - | -100.0K | - |
| Total Current Assets | 2.7B | 2.5B | 3.1B | 2.3B | 2.3B |
| Non-Current Assets | |||||
| Property, Plant & Equipment | 87.0M | 86.9M | 87.0M | 950.6M | 1.9B |
| Goodwill | 10.0B | 10.5B | 9.9B | 10.0B | 9.1B |
| Intangible Assets | 689.9M | 787.9M | 796.0M | 919.0M | 895.7M |
| Long-term Investments | - | - | - | - | - |
| Other Non-Current Assets | - | - | - | - | - |
| Total Non-Current Assets | 8.3B | 8.4B | 7.8B | 7.8B | 7.0B |
| Total Assets | 11.0B | 10.9B | 10.9B | 10.1B | 9.3B |
| Liabilities | |||||
| Current Liabilities | |||||
| Accounts Payable | 678.1M | 645.9M | 600.2M | 647.7M | 627.6M |
| Short-term Debt | 726.7M | 478.8M | 601.0M | 213.7M | 253.9M |
| Current Portion of Long-term Debt | - | - | - | - | - |
| Other Current Liabilities | 100.0K | -100.0K | 100.0K | - | -200.0K |
| Total Current Liabilities | 2.4B | 2.1B | 2.1B | 1.8B | 1.9B |
| Non-Current Liabilities | |||||
| Long-term Debt | 3.7B | 3.1B | 3.3B | 3.1B | 2.5B |
| Deferred Tax Liabilities | 121.1M | 109.5M | 110.0M | 133.6M | 123.6M |
| Other Non-Current Liabilities | 100.0K | - | 100.0K | - | 200.0K |
| Total Non-Current Liabilities | 4.0B | 3.4B | 3.6B | 3.5B | 2.8B |
| Total Liabilities | 6.4B | 5.5B | 5.8B | 5.2B | 4.7B |
| Equity | |||||
| Common Stock | 1.8M | 1.9M | 1.9M | 1.9M | 1.9M |
| Retained Earnings | 3.0B | 2.7B | 2.4B | 2.3B | 2.0B |
| Treasury Stock | 298.9M | 307.8M | 54.9M | 14.2M | 3.6M |
| Other Equity | - | - | - | - | - |
| Total Shareholders Equity | 4.6B | 5.4B | 5.1B | 4.9B | 4.7B |
| Key Metrics | |||||
| Total Debt | 4.4B | 3.6B | 3.9B | 3.3B | 2.8B |
| Working Capital | 223.9M | 342.0M | 944.7M | 541.1M | 463.3M |
Balance Sheet Composition
Eurofins Scientific Cash Flow Statement From 2021 to 2025
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Operating Activities | |||||
| Net Income | 654.1M | 554.6M | 423.3M | 780.0M | 1.1B |
| Depreciation & Amortization | - | - | - | - | - |
| Stock-Based Compensation | 138.1M | 138.3M | 137.7M | 136.1M | 131.0M |
| Working Capital Changes | -3.8M | 47.0M | -11.1M | 61.4M | -96.7M |
| Operating Cash Flow | 893.7M | 855.6M | 655.9M | 1.1B | 1.3B |
| Investing Activities | |||||
| Capital Expenditures | -745.7M | -443.4M | -471.7M | -561.2M | -419.6M |
| Acquisitions | -264.2M | -344.3M | -150.8M | -214.7M | -532.6M |
| Investment Purchases | - | - | - | - | - |
| Investment Sales | - | - | - | - | - |
| Investing Cash Flow | -1.0B | -787.8M | -622.6M | -775.8M | -952.3M |
| Financing Activities | |||||
| Share Repurchases | -541.3M | -271.9M | -55.8M | -15.8M | -3.6M |
| Dividends Paid | -107.7M | -95.6M | -191.9M | -192.1M | -130.4M |
| Debt Issuance | 1.2B | 118.0M | 638.5M | 633.9M | 826.3M |
| Debt Repayment | -310.9M | -477.7M | -90.0M | -82.9M | -1.3B |
| Financing Cash Flow | 210.0M | -780.5M | 677.5M | -95.4M | -588.1M |
| Free Cash Flow | 564.1M | 790.5M | 467.8M | 476.1M | 1.0B |
| Net Change in Cash | 93.7M | -712.7M | 710.8M | 227.4M | -257.9M |
Cash Flow Trend
Eurofins Scientific Key Financial Ratios
Valuation Ratios
P/E Ratio (TTM)
24.24
Forward P/E
13.25
Price to Book
3.08
Price to Sales
1.48
Profitability Ratios
Profit Margin
6.51%
Operating Margin
13.25%
Return on Equity
9.50%
Return on Assets
5.51%
Financial Health
Current Ratio
1.09
Debt to Equity
96.84
Beta
0.91
Per Share Data
EPS (TTM)
€2.55
Book Value per Share
€20.05
Revenue per Share
€40.58
Peer Financial Comparison
| Company | Market Cap | P/E Ratio | P/B Ratio | ROE | Profit Margin | Debt/Equity |
|---|---|---|---|---|---|---|
| ERF | 10.8B | 24.24 | 3.08 | 9.50% | 6.51% | 96.84 |
| bioMérieux S.A | 8.4B | 21.24 | 2.04 | 9.54% | 9.77% | 11.24 |
| Lumibird S.A | 540.6M | 38.59 | 2.64 | 6.93% | 6.13% | 70.86 |
| Eurofins Cerep SAS | 79.7M | 12.94 | - | 8.74% | 15.86% | 0.10 |
| Klea Holding | 54.0M | 17.58 | 1.98 | 9.14% | 11.89% | 18.40 |
| Predilife S.A | 12.2M | - | - | -4,653.75% | 97.76% | -1.15 |
Financial data is updated regularly. All figures are in the company's reporting currency.